Concepedia

Christopher A. Yasenchak

CA

Statistics

Publications

22

Citations

904

H-Index

16

Active since

2006

Affiliations

Willamette Valley Cancer Institute and Research Center(Current)

Texas Oncology

Seagen (United States)

Virginia Cancer Specialists

Arizona Oncology

Christopher A. Yasenchak is an author at Willamette Valley Cancer Institute and Research Center specializing in medicine, oncology, and hematologic malignancy therapy.

ORCID

Publications per year

2006–2025

22

Publications

22

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

, , +12

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Andres Forero‐Torres, Beata Holkova, Jerome H. Goldschmidt et al. · Blood · 2015 · 142 citations · Full text

, , +11

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Jonathan W. Friedberg, Andres Forero‐Torres, Rodolfo Bordoni et al. · Blood · 2017 · 90 citations · Full text

, , +3

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

David Andorsky, Kathryn S. Kolibaba, Sarit Assouline et al. · British Journal of Haematology · 2018 · 47 citations · Full text

, , +17

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

Nancy L. Bartlett, Uwe Hahn, Won Seog Kim et al. · Journal of Clinical Oncology · 2025 · 39 citations · Full text

, , +15

1–5 of 22